Compass Pathways Files NDA for COMP360 Psilocybin in U.S. TRD

Compass Pathways Submits First Psilocybin NDA to FDA

Compass Pathways announced on November 9, 2026, that it has completed submission of a New Drug Application (NDA) for COMP360, a proprietary psilocybin formulation, to the U.S. Food and Drug Administration (FDA) for the indication of treatment-resistant depression (TRD). This marks the first time a modern psychedelic-based therapy has reached this regulatory milestone in the United States, representing a pivotal moment for the field of psychedelic medicine. If the FDA accepts the NDA for review, COMP360 could become the first psilocybin-based medication to receive federal approval for a mental health indication.

Mechanism, Clinical Evidence, and Regulatory Context

COMP360 is a synthetic, high-purity psilocybin administered in conjunction with psychological support in a controlled clinical setting. The NDA submission follows the completion of Compass Pathways' Phase 3 program, which included two pivotal trials (NCT05149502 and NCT05322954) enrolling adults with TRD who had failed at least two prior antidepressant regimens. In these studies, COMP360 demonstrated statistically significant reductions in depressive symptoms at three weeks post-administration compared to placebo, with effects persisting for some participants at 12 weeks. Adverse events included headache, transient anxiety, and in rare cases, suicidal ideation, underscoring the need for careful patient selection and monitoring.

The FDA has previously granted COMP360 Breakthrough Therapy Designation, expediting its development and review. The NDA package includes efficacy and safety data, manufacturing controls, and a proposed Risk Evaluation and Mitigation Strategy (REMS) to address the unique safety profile of psilocybin. The FDA’s decision to accept the application for review is expected within 60 days of submission, with a potential PDUFA (Prescription Drug User Fee Act) target action date in late 2027.

Policy, Access, and Research Implications

If approved, COMP360 would become the first federally sanctioned psilocybin therapy in the U.S., with broad implications for clinical practice, research funding, and payer policy. FDA approval would likely make psilocybin-assisted therapy eligible for insurance reimbursement, subject to REMS requirements and certified provider training. This could catalyze the development of new clinical infrastructure, including specialized treatment centers and therapist certification programs, while also prompting updates to state and federal scheduling of psilocybin.

Importantly, the NDA process requires the sponsor to propose a post-marketing surveillance plan. This is a non-obvious but critical lever: the scope and rigor of post-approval data collection could shape real-world adoption, payer confidence, and future regulatory requirements for other psychedelic compounds. Stakeholders should closely monitor the FDA’s REMS negotiations and post-market study mandates, as these will set precedents for the entire field.

Risks, Unknowns, and Cautions

While COMP360 has shown promise in controlled trials, significant risks and unknowns remain. The durability of antidepressant effects beyond 12 weeks is unclear, and relapse rates in real-world populations may differ from trial cohorts. Safety concerns include the potential for psychological distress, misuse, and rare but serious adverse events such as self-harm. The REMS framework will be essential in mitigating these risks, but it may also limit access by requiring administration in certified facilities under direct supervision.

Another unresolved issue is the generalizability of trial results to diverse patient populations. Most participants in COMP360 studies were white, middle-aged, and had access to comprehensive mental health support, raising questions about equity and effectiveness in broader clinical practice. Furthermore, the cost and logistics of psychedelic-assisted therapy—typically involving multiple preparatory and integration sessions—may challenge scalability and reimbursement models.

Looking Ahead: What Comes Next?

The FDA’s review of the COMP360 NDA will be closely watched by researchers, clinicians, payers, and policymakers. A positive decision could accelerate investment and research across the psychedelic sector, while a rejection or restrictive REMS could temper expectations. Regardless of outcome, the NDA sets a regulatory template for future psychedelic therapies, and the FDA’s approach to post-marketing surveillance will influence the pace and direction of subsequent drug development.

As the field awaits the FDA’s decision, stakeholders should prepare for rapid shifts in clinical guidelines, payer policy, and public discourse. The COMP360 NDA is not just a milestone for Compass Pathways, but a bellwether for the future of psychedelic medicine in the United States.

By Dr. Alex Greene, PhD (Neuroscience, Regulatory Science Editor). Reviewed by Dr. Maya Patel, MD (Psychiatry) on 2026-11-10. Research based on FDA filings, clinical trial registries, and Compass Pathways press releases.